Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
21 – 65
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Basic Science
Participants needed
20 (estimated)
Sponsor
Johns Hopkins University · Other
Who this trial is looking for
This trial is looking for healthy adults aged 21 to 65 to test the effects of a single dose of psilocybin, with or without another medication. Participants will be monitored for their mood and well-being over the course of one month.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 21 and 65 years old.
I can read and speak English.
I have completed at least high school.
I am right-handed.
I agree to not use any psychoactive drugs the day before and the day of the drug session.
I will consume my usual amount of caffeine on drug session days.
I am willing to refrain from nonprescription medications one week before the drug session.
If I am female and can become pregnant, I will use effective contraception.
You may not be able to join if
I am left-handed.
I have used psychedelics or certain drugs in the past.
I have a history of psychiatric disorders as an adult.
I currently take neuropsychiatric medications.
I have a current substance use disorder.
I have had significant suicidal thoughts in the past 6 months.
I use illegal drugs or have tested positive for them recently.
I have a family history of schizophrenia or certain mood disorders.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration.
The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effec…
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration.
The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures. These mechanisms will be examined using psychometric scales, autonomic and fMRI-based neurophysiologic markers, and integrated pharmacokinetic/pharmacodynamic modeling.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Age 21 to 65 years old
* Provision of written informed consent
* Fluency in English
* At least high school level of education
* Right-handed
* Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session as demonstrated by a n…
Inclusion Criteria:
* Age 21 to 65 years old
* Provision of written informed consent
* Fluency in English
* At least high school level of education
* Right-handed
* Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session as demonstrated by a negative toxicology report.
* Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days.
* Agree not to take any PRN medications on the mornings of drug sessions
* Agree that for one week before the drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
* Female participants of childbearing potential must agree to use a highly effective method of contraception throughout the study.
* Highly effective methods are defined as those that, when used consistently and correctly (alone or in combination), are associated with a failure rate of less than 1% per year.
* Condoms alone are not considered highly effective.
* Abstinence is not considered a highly effective method. However, at the investigator's discretion, abstinence may be accepted if, based on the investigator's judgment and knowledge of the participant's usual and preferred lifestyle, it can be reasonably expected to result in 100% effectiveness.
Exclusion Criteria:
* Non-English speakers and those with language or hearing impairments
* Left-handedness (assessed by the Edinburgh Handedness Inventory)
* Any lifetime history of psychedelic use, including serotonergic compounds (e.g., psilocybin, LSD, mescaline, DMT, 5-MeO-DMT) and nontraditional psychedelics (e.g., MDMA, ketamine, ibogaine)
* History of psychiatric diagnosis in adulthood (≥18 years), including, but not limited to, major depressive disorder, bipolar disorder I and II, psychotic disorders, and substance use disorder.
* Current use of neuropsychiatric medications, including but not limited to typical/atypical antidepressants, antipsychotics, and stimulants.
* Lifetime history of substance use disorder
* Current (within past six months) substance use disorder of moderate or greater severity
* Clinically significant suicidal ideation (with strong intent or means) within the past 6 months or lifetime history of suicide attempt, current suicidal ideation, or otherwise judged by a study clinician to be more than low risk for suicidality
* Current use/positive toxicology for illicit drugs at screening and prior to drug administration session (includes illicit, non-prescribed, or prohibited substances such as amphetamines, barbiturates, buprenorphine, benzodiazepines, cocaine, MDMA, methadone, opioids, phencyclidine (PCP), and tetrahydrocannabinol (THC))
* Nicotine user consuming the equivalent of ≥ 10 cigarettes/day
* Altered gastrointestinal anatomy \[history of surgeries that promote a general intestinal malabsorption (e.g., jejunoileal bypass, jejunocolic bypass, roux-en-Y gastric bypass, vertical banded gastroplasty, gastric band, gastric stapling, sleeve gastrectomy, biliopancreatic diversion with partial gastrectomy, distal gastric bypass, duodenal switch)\]
* Weight \< 40kg
* Have a first degree relative with schizophrenia or other psychotic disorders (except substance/medication-induced or due to another medical condition), or bipolar I disorder
* MRI contraindications (e.g., claustrophobia incompatible with MRI scanning, medical device or implant incompatible with MRI, prior history as a metal worker and/or certain metallic objects in the body). Must complete MRI screening form and be approved by MRI technologist before each scan.
* Unable or unwilling to perform study procedures, or inappropriate for further study participation as determined by the PI and/or study clinicians
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.